



## Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)

PATIENT INFORMATION (Complete or Fax Existing	ng Chart) PRESCRIBER INFORMATION	PRESCRIBER INFORMATION			
Name: DOB:	Prescriber Name:	Prescriber Name:			
Address:	State License:	_			
City, State, Zip:					
Phone: Alt. Phone:	Address:	Address:			
Email: SS#:		City, State, Zip:			
Gender: $\square$ M $\square$ F Weight:(lbs) Ht:		Phone: Fax:			
Allergies:	Office Contact: Phone:	Office Contact: Phone:			
INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)					
Primary Insurance:	Secondary Insurance (If Applicable):	Secondary Insurance (If Applicable):			
Plan #:	Plan #:	Plan #:			
Group #:	Group #:	Group #:			
RX Card (PBM):	RX Card (PBM):	RX Card (PBM):			
BIN: PCN:		BIN: PCN:			
CLINICAL INFORMATION					
Primary ICD-10 Code (Please Specify Diagnosis):					
Secondary ICD-10 Code (Please Specify Diagnosis):					
Date of negative TB test:					
History of kidney disease: ☐ Yes ☐ No If yes, SCr: GFR/CrCl: History of heart failure: ☐ Yes ☐ No					
	Required Labs/Results:  ANC:  Platelet:  SCr:  Lipids:  Lipids:				
	elet:				
Required Labs/Results:   ANC:   Plate	elet:				
Required Labs/Results:   ANC:   Plate					
Required Labs/Results:  ANC:  Dispersion of normal:  ACTEMRA® ORDERS					
Required Labs/Results:  ANC:  Dispersion of normal:  ACTEMRA® ORDERS	☐ ALT: Upper limit of normal:				
Required Labs/Results:  ANC:  Dispersion Plate  ACTEMRA® ORDERS  Prescription type:  New start  Restart  Continued the Medication  Strength	Date of Last Injection/Infusion:				
Required Labs/Results:  ANC:  Dispersion Plate  ACTEMRA® ORDERS  Prescription type:  New start  Restart  Continued the Medication  Strength	□ ALT:Upper limit of normal:  therapy Total Doses Received: Date of Last Injection/Infusion:  Dose/Frequency Refills				
Required Labs/Results:  ANC: Plate  AST: Upper limit of normal:  ACTEMRA® ORDERS  Prescription type:  New start Restart Continued the  Medication Strength  Actemra (Tocilizumab)	Date of Last Injection/Infusion:  Dose/Frequency  Aug/kg IV every 4 weeks with max dose of 600 mg for weight >100 kg  Geng/kg IV every 4 weeks with max dose of 600 mg for weight >100kg  May be				
Required Labs/Results:  ANC: Plate  AST: Upper limit of normal:  ACTEMRA® ORDERS  Prescription type:  New start Restart Continued the  Medication Strength  Actemra (Tocilizumab)	□ ALT:Upper limit of normal:  therapy Total Doses Received: Date of Last Injection/Infusion:  Dose/Frequency Refills  □ 4mg/kg IV every 4 weeks with max dose of 800 mg for weight >100 kg  □ 6mg/kg IV every 4 weeks with max dose of 600 mg for weight >100kg				
Required Labs/Results:  ANC: Plate  AST: Upper limit of normal:  ACTEMRA® ORDERS  Prescription type:  New start Restart Continued the  Medication Strength  Actemra (Tocilizumab)	Date of Last Injection/Infusion:  Dose/Frequency  Aug/kg IV every 4 weeks with max dose of 600 mg for weight >100 kg  Geng/kg IV every 4 weeks with max dose of 600 mg for weight >100kg  May be				
Required Labs/Results:  ANC:  Plate AST:  Upper limit of normal:  ACTEMRA® ORDERS  Prescription type:  New start  Restart  Continued the Medication Strength  Actemra (Tocilizumab)  20mg/mL vial  Other:    Other:  Image: Plate of	Date of Last Injection/Infusion:  Dose/Frequency  Aug/kg IV every 4 weeks with max dose of 600 mg for weight >100 kg  Geng/kg IV every 4 weeks with max dose of 600 mg for weight >100kg  May be				
Required Labs/Results:  ANC:  Plate AST:  Upper limit of normal:  ACTEMRA® ORDERS  Prescription type:  New start  Restart  Continued the Medication Strength  Actemra (Tocilizumab)	Date of Last Injection/Infusion:  Dose/Frequency  Aug/kg IV every 4 weeks with max dose of 600 mg for weight >100 kg  Geng/kg IV every 4 weeks with max dose of 600 mg for weight >100kg  May be				
Required Labs/Results:  ANC:  Plate AST:  Upper limit of normal:  ACTEMRA® ORDERS  Prescription type:  New start  Restart  Continued the Medication Strength  Actemra (Tocilizumab)  20mg/mL vial  Other:  INFUSION REACTION ORDERS  Mild reaction protocol:	□ ALT:				
Required Labs/Results: ANC: Plate AST: Upper limit of normal:  ACTEMRA® ORDERS  Prescription type: New start Restart Continued the Medication Strength  Actemra (Tocilizumab) 20mg/mL vial Other:  INFUSION REACTION ORDERS  Mild reaction protocol: Diphenhydramine 25mg IV, one time, for pruritus. If symptoms worsen, see orders for moderate to severe reaction Moderate reaction protocol:	□ ALT:				
Required Labs/Results: □ ANC: □ □ Plate □ AST: □ Upper limit of normal: □  ACTEMRA® ORDERS  Prescription type: □ New start □ Restart □ Continued the Medication Strength □ Actemra (Tocilizumab) □ 20mg/mL vial □ Other: □ □ INFUSION REACTION ORDERS  Mild reaction protocol: □ Diphenhydramine 25mg IV, one time, for pruritus. If symptoms worsen, see orders for moderate to severe reaction Moderate reaction protocol: □ Accetaminophen 650mg PO, one time, for pyrexia or rigors	Date of Last Injection/Infusion:    Dose/Frequency				
Required Labs/Results: ANC: Plate  AST: Upper limit of normal:  ACTEMRA® ORDERS  Prescription type: New start Restart Continued the Medication Strength  Actemra (Tocilizumab)	Date of Last Injection/Infusion:   Dose/Frequency   Refills				
Required Labs/Results:  ANC:  Plate  Plate  Plate  AST:  Upper limit of normal:    ACTEMRA® ORDERS  Prescription type:  New start  Restart  Continued the  Medication  Strength    Actemra (Tocilizumab)  Other:    INFUSION REACTION ORDERS  Mild reaction protocol:  Oil phenhydramine 25mg IV, one time, for pruritus.    If symptoms worsen, see orders for moderate to severe reaction    Moderate reaction protocol:  Acetaminophen 650mg PO, one time, for pyrexia or rigors    Diphenhydramine 50mg IV, one time, for pruritus or urtical    Methylprednisolone 125mg IV, one time, for respiratory one	Date of Last Injection/Infusion:   Dose/Frequency   Refills				
Required Labs/Results:  ANC:  Plate  Plate  AST:  Upper limit of normal:    ACTEMRA® ORDERS  Prescription type:  New start  Restart  Continued the  Medication  Strength    Actemra (Tocilizumab)  Other:    INFUSION REACTION ORDERS  Mild reaction protocol:  Oiphenhydramine 25mg IV, one time, for pruritus.    If symptoms worsen, see orders for moderate to severe reaction    Moderate reaction protocol:  Acetaminophen 650mg PO, one time, for pyrexia or rigors    Diphenhydramine 50mg IV, one time, for pruritus or urtical    Methylprednisolone 125mg IV, one time, for respiratory on    If symptoms worsen, see interventions for severe reactions	Date of Last Injection/Infusion:   Dose/Frequency   Refills				
Required Labs/Results:  ANC: Plate  Plate  AST: Upper limit of normal:   ACTEMRA® ORDERS  Prescription type:  New start  Restart  Continued the  Medication  Strength    Actemra (Tocilizumab)	Total Doses Received: Date of Last Injection/Infusion:  Dose/Frequency Refills    4mg/kg IV every 4 weeks with max dose of 800 mg for weight >100 kg   6mg/kg IV every 4 weeks with max dose of 600 mg for weight >100kg   8 mg/kg IV every 4 weeks with max dose of 800 mg for weight >100kg   Other:				
Required Labs/Results:  ANC: Plate  Plate  AST: Upper limit of normal:   ACTEMRA® ORDERS  Prescription type:  New start  Restart  Continued the  Medication  Strength    Actemra (Tocilizumab)					

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.





## Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)

☑ Sodium Chloride 0.9% 500mL IV over 30-60 min, one time, for cardiovascular symptoms						
☑ Epinephrine 0.3mg/0.3mL IM into mis-anterolateral aspect of thigh of anaphylaxis, may repeat x1 in 5-15 minutes if symptoms are not resolved or						
worsen						
WOISEII						
FLUSHING & LOCKING ORDERS						
Flushing Protocol (>66lbs/33kg)						
PIV and Midline:		Implanted Port, PICC, Tunneled Catheter, and Non-tunneled Catheter:				
☑ 0.9% Sodium Chloride 2-5mL IV flush before and after each infusion		☑ 0.9% Sodium Chloride 5mL IV flush before infusion/lab draw and 10mL				
		IV flush after infusion/lab draw				
Locking Protocol (>66lbs/33kg)						
PIV and Midline:	PICC:		Implanted Port, Tunneled Catheter, and Non-			
☐ Heparin Sodium 10 units/mL 1mL IV final	☑ Heparin Sodium 10 units/mL 3mL IV final		tunneled Catheter:			
flush post normal saline flush	flush post normal saline flush					
			flush post normal saline flush			
** May substitute Dextrose 5% in Water, or alternative, for 0.9& Sodium Chloride, when indicated due to incompatibility with medications bring infused						
SIGNATURE						
We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.						
X Date:						
Prescriber Signature						

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.